AB-MDMSBA is a novel synthetic compound that has been sold as a designer drug. It has been detected by drug checking services in Australia and New Zealand being misrepresented as a benzodiazepine.
It is structurally similar to other arylsulfonamide-based synthetic cannabinoids such as QMPSB. This class of synthetic cannabinoid has previously been targeted toward greater selectivity of the cannabinoid receptor CB2 over CB1. However, AD-MDMSBA itself binds with very low affinity and is unlikely to cause receptor activation. It may serve as a pre-cursor to synthesize other cannabinoids.
See also 2F-QMPSB
References